ReviewAAPS PharmSciTech2024
Cyclodextrin Drugs in Liposomes: Preparation and Application of Anticancer Drug Carriers.
Review in AAPS PharmSciTech, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Alkaloid-based nanodrug delivery systems: An emerging strategy against drug-resistant bacterial wound infections.International journal of pharmaceutics: X · 2026Review
- Formulation Strategies to Enhance the Solubility of Poorly Water-Soluble Drugs and Phytochemicals: Current Advances and Challenges.Pharmaceutics · 2026Review
- Liposomal Encapsulation of Camptothecin/Carboxymethyl-β-Cyclodextrin Complexes: Stability, Solubility and Cytotoxicity.International journal of molecular sciences · 2026Article
- Thermally Stable Nanoarchitectonics of Bicellar Nanocarriers for Superior Transdermal Delivery ofACS applied materials & interfaces · 2026Article
- Improved Encapsulation and Potential of Liposomal Tosufloxacin via Inclusion in Cyclodextrin.AAPS PharmSciTech · 2025Article
- In Situ Targeting RGD-Modified Cyclodextrin Inclusion Complex/Hydrogel Hybrid System for Enhanced Glioblastoma Therapy.Pharmaceutics · 2025Article
- Application of β-cyclodextrin and pickering emulsion to enhance the ozone stability of Acorus tatarinowii and Atractylodes lancea volatile oils.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyclodextrin complexes have been widely used in pharmaceutical applications, but disadvantages such as the rapid clearance of cyclodextrins from the blood stream after in vivo administration or their replacement by other molecules in the biological medium with higher luminal affinity for cyclodextrins limit the application of cyclodextrins as drug carriers. Liposome-encapsulated hydrophobic drugs have low and unstable drug loading rates. Drug-in-CD-in-liposome (DCL), which encapsulate cyclodextrin inclusion complexes into liposomes, combine the advantages of both delivery systems, can effectively avoid the leakage and rapid release of lipophilic drugs in the lipid bilayer, and help to maintain the integrity of liposomes. This paper focuses on the preparation method, characterization and application of DCL, with a view to providing methods and references for the research and application of DCL technology.
Indexed as
Identifiers
39638889What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.